Peter Lacamera is a Respiratory physician affiliated with Boston Medical Center. OpenAlex indexes 45 publications with 1,441 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
736 Cambridge St.
Pulmonary
Boston, MA 021352907
Telephone
617-789-2545Provider last certified this registry record 13 Mar 2025.
Clinical trials
- Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes
Sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20231 payment
- United Therapeutics CorporationProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
83.4%Corticosteroid46%Trelegy Ellipta65%Breo Ellipta11%Arnuity Ellipta8%Fluticasone Propionate8%Symbicort6%Qvar Redihaler2%Part D<11 patientsbeta2-Adrenergic Agonist29.2%Albuterol Sulfate Hfa72%Ventolin Hfa23%Serevent Diskus5%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
9.1%Corticosteroid6%Prednisone100%Part D≥31 patientsProton pump inhibitor1.6%Omeprazole100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
4.5%Kinase inhibitor4.5%Ofev100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Devastating Demise: Acute Respiratory Distress Syndrome From Rapidly-Progressive Interstitial Lung Disease
American Journal of Respiratory and Critical Care Medicine
2025 - National Estimates and Predictors for Asthma Readmissions for the Years 2010 and 2019
American Journal of Respiratory and Critical Care Medicine
2025 - Frequency and Time Course of Lung Cancer Diagnoses Following Lung-RADS 3 Studies
American Journal of Respiratory and Critical Care Medicine
2025 - Diagnostic Yield of 19G vs 21G EBUS-TBNA Needles for PD-L1 Testing
American Journal of Respiratory and Critical Care Medicine
2025 - Gasping for Air: A Dynamic Case of Chlorine Gas Exposure
American Journal of Respiratory and Critical Care Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Alice Jacobs, MD
Boston Medical Center
Carlos Kase, MD
Boston Medical Center
Sushrut Waikar, MD
Boston Medical Center
Geoffrey Oxnard, MD
Boston Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”